Literature DB >> 21800802

Uveitis following intravitreal bevacizumab: a non-infectious cluster.

Christine N Kay1, Ryan M Tarantola, Karen M Gehrs, James C Folk, Vinit B Mahajan, H Culver Boldt, Nasreen A Syed, Stephen R Russell.   

Abstract

BACKGROUND AND
OBJECTIVE: In this retrospective case series, the authors report seven cases of bevacizumab-related uveitis that occurred within a 4-month period. PATIENTS AND METHODS: Seven eyes of six patients developed non-infectious uveitis following bevacizumab intravitreal injections in a cohort of 978 consecutive bevacizumab injections.
RESULTS: The mean age of patients was 74.6 years (range: 26 to 92). All patients developed symptom onset within 1 day of injection. Shared signs and symptoms included corneal edema, anterior chamber and vitreous cell, conjunctival injection, ocular pain, and lack of hypopyon. In all patients, visual acuity returned to within one line of baseline acuity. All seven eyes had been previously injected with bevacizumab, with a mean number of antecedent injections of 6.1 (range: 3 to 12).
CONCLUSION: A cluster of sterile bevacizumab-related uveitic reactions was described in this case series. Acute onset of symptoms, absence of hypopyon, a predominant anterior segment reaction, and prompt improvement on topical steroid therapy are useful clinical features distinguishing this uveitic syndrome from infectious endophthalmitis. Copyright 2011, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21800802     DOI: 10.3928/15428877-20110603-04

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  10 in total

1.  Quality of bevacizumab compounded for intravitreal administration.

Authors:  J M Palmer; W M Amoaku; F Kamali
Journal:  Eye (Lond)       Date:  2013-06-21       Impact factor: 3.775

2.  Sterile Inflammation after Intravitreal Injection of Aflibercept in a Korean Population.

Authors:  Ju Young Kim; Yong Sung You; Oh Woong Kwon; Soon Hyun Kim
Journal:  Korean J Ophthalmol       Date:  2015-09-22

Review 3.  Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review.

Authors:  William J Anderson; Natasha Ferreira Santos da Cruz; Luiz Henrique Lima; Geoffrey G Emerson; Eduardo Büchele Rodrigues; Gustavo Barreto Melo
Journal:  Int J Retina Vitreous       Date:  2021-05-07

Review 4.  Sterile endophthalmitis after intravitreal injections.

Authors:  Joaquín Marticorena; Vito Romano; Francisco Gómez-Ulla
Journal:  Mediators Inflamm       Date:  2012-08-29       Impact factor: 4.711

5.  Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab.

Authors:  Christina Antonopoulos; Maxwell Stem; Grant M Comer
Journal:  Clin Ophthalmol       Date:  2011-11-24

6.  Comparison of microbiology and visual outcomes of patients undergoing small-gauge and 20-gauge vitrectomy for endophthalmitis.

Authors:  David Rp Almeida; Eric K Chin; Shaival S Shah; Benjamin Bakall; Karen M Gehrs; H Culver Boldt; Stephen R Russell; James C Folk; Vinit B Mahajan
Journal:  Clin Ophthalmol       Date:  2016-01-22

7.  Drug-induced uveitis.

Authors:  Nikolas Js London; Sunir J Garg; Ramana S Moorthy; Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-03-25

Review 8.  Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.

Authors:  Shivi Agrawal; Malav Joshi; John B Christoforidis
Journal:  Mediators Inflamm       Date:  2013-11-06       Impact factor: 4.711

9.  Causative Pathogens in Endophthalmitis after Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents.

Authors:  Cecilia P Labardini; Eytan Z Blumenthal
Journal:  Rambam Maimonides Med J       Date:  2018-09-02

Review 10.  Postoperative Endophthalmitis and Toxic Anterior Segment Syndrome Prophylaxis: 2020 Update.

Authors:  Jesse D Sengillo; Ying Chen; Diley Perez Garcia; Stephen G Schwartz; Andrzej Grzybowski; Harry W Flynn
Journal:  Ann Transl Med       Date:  2020-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.